DBS denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for dbs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues Not-FDA-Approved Denials for Deep Brain Stimulation (DBS)

Deep brain stimulation devices are FDA-regulated under the premarket approval (PMA) pathway, and FDA-approved DBS systems exist for several neurological indications. A "not-FDA-approved" denial from BCBS most commonly occurs in one of three scenarios: (1) the requested DBS use is for an indication not listed in the FDA device approval (off-label use); (2) the specific device model or firmware version requested has not yet received FDA clearance; or (3) a BCBS reviewer or automated system applied the wrong review criteria and mischaracterized an FDA-approved use as unapproved. Scenario three is surprisingly common and is resolved by providing the FDA approval documentation directly.

## Why This Denial Is Appealable

For FDA-approved DBS indications and devices, the "not-FDA-approved" basis is factually incorrect and should be overturned promptly upon submission of the relevant FDA approval documents. For off-label uses, the situation is more complex — insurance coverage of off-label device use is governed by plan contract language and medical policy, not by FDA approval status alone, so the appeal should reframe the argument around medical necessity and clinical evidence rather than FDA labeling. In either case, the denial is contestable.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on your denial letter. BCBS must respond within 30 days for pre-service non-urgent or 72 hours for expedited/urgent cases.
• Factual correction submission: If the denial rests on a factual error about FDA status, provide FDA documentation at the internal-appeal stage — this alone may resolve the denial without requiring external review.
• External review (ACA §2719): After final internal denial, request independent external review within approximately four months. External reviewers apply clinical and regulatory standards independently of BCBS.
• State insurance commissioner: If BCBS continues to misrepresent FDA approval status after documentation is provided, a state insurance department complaint is appropriate.

## Documentation to Gather

1. FDA approval/clearance documentation — obtain the FDA's PMA approval letter or 510(k) clearance for the specific DBS device system and the applicable indication from the FDA website (fda.gov). 2. Device labeling/IFU — the manufacturer's Instructions for Use showing the approved indications. 3. Prescriber letter addressing FDA status — your neurosurgeon should confirm that the requested use is within FDA-approved labeling, or — for off-label use — should explain the evidence base and medical necessity. 4. Clinical records — diagnosis, prior treatment history, and specialist evaluation supporting medical necessity. 5. Specialty-society guidelines — relevant guidance from neurology or neurosurgery societies supporting the proposed use.

## Criteria-Mapping Structure

For each basis cited in the denial, prepare a direct rebuttal:

| Denial Basis | Rebuttal Document | |---|---| | Device not FDA-approved | FDA PMA approval letter for device + indication | | Use is off-label | Published evidence + prescriber rationale + society guideline | | Indication not covered under policy | BCBS policy criteria mapping + medical necessity letter | | Device model not recognized | Manufacturer documentation + FDA clearance |

Attaching the actual FDA approval document as the first exhibit in an appeal for a "not-FDA-approved" denial is often sufficient to resolve it at the internal level — reviewers can make factual corrections without requiring a full medical review.